cover
Contact Name
Syafira Dwi Cahyani
Contact Email
adminjifi@univpancasila.ac.id
Phone
+6287780957284
Journal Mail Official
syafira.ffup@univpancasila.ac.id
Editorial Address
Editorial Office: Lenteng Agung St, Srengseng Sawah District, Jagakarsa Regency, Jakarta Selatan, Special Region of Jakarta 12640, Indonesia.
Location
Kota adm. jakarta selatan,
Dki jakarta
INDONESIA
Jurnal Ilmu Kefarmasian Indonesia
Published by Universitas Pancasila
ISSN : 16931831     EISSN : 26146495     DOI : -
Core Subject : Health, Science,
Jurnal Ilmu Kefarmasian Indonesia (JIFI) mainly focuses on a current topic in Pharmaceutical Sciences are also considered for publication by the Journal. Discussions on a topic in Pharmaceutical Sciences, Clinical Sciences, and Social Behaviour Administration. Detailed scopes of articles accepted for submission to JIFI are: 1. Pharmaceutical Biology 2. Pharmaceutical Chemistry. 3. Pharmaceutical Technology. 4. Biomedical and Clinical Pharmacy. 5. Social Pharmacy and Administration.
Articles 1 Documents
Search results for , issue "Vol. 18 No. 2 (2020): JIFI" : 1 Documents clear
Analisis Efektivitas Biaya Pengobatan Kombinasi Zidovudin, Lamivudin, Nevirapin dan Kombinasi Tenofovir, Lamivudin, Efavirenz Pada Pasien HIV/AIDS di RSUD Kota Bekasi: COST EFFECTIVENESS ANALYSIS OF ZIDOVUDIN, LAMIVUDIN, NEVIRAPIN (AZT (300)/3TC (150) / NVP (200)) AND TENOFOVIR, LAMIVUDIN, EFAVIRENZ (TDF (300) / 3TC (150) / 3TC (150) / NVP (200)) AND TENOFOVIR, LAMIVUDIN, EFAVIRENZ (TDF (300) / 3TC (150) / 3TC (150) / NVP (200)) / AIDS IN BEKASI HOSPITAL Anggriani, Yusi; Purba, Fredrick Dermawan; Manninda, Reise; Tarsinah, Tarsinah
JURNAL ILMU KEFARMASIAN INDONESIA Vol. 18 No. 2 (2020): JIFI
Publisher : Faculty of Pharmacy, Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v18i2.905

Abstract

HIV/AIDS has become a global issue in many countries. The implementation of ARV / HAARTprograms is always changing, due to clinical reasons, population factors, and aff ordability. Pharmacoeconomic studies can be one of the considerations in the policy process for procurement and selection of therapy regimens. The aims of this study were to determine the eff ectiveness of treatment based on CD4 increase and cost eff ectiveness analysis of HAART A and HAART B treatment regimens. This study used a cross sectional observation method. Retrospective data collection and non-experimental observation where conducted followes by a quantitative descriptive analysis according to the patient's perspective to obtain costeffectiveness data. Data were statistically analyzed to obtain the cost-eff ectiveness of treatment. The results showed that the cost-eff ectiveness analysis (CEA) of two regimens found that HAART A was more dominant than HAART B with a signifi cant diff erence p<0.05. While ACER regimen HAART A (16,227) was greater than the value ACER therapy B (28,330.7).

Page 1 of 1 | Total Record : 1